Other classical forms of neuropathic pain include diabetic peripheral neuropathy, trigeminal neuralgia and postherpetic
|
|
- Samuel Casey
- 5 years ago
- Views:
Transcription
1 Guideline Name: Neuropathic Pain Neuropathic pain is defined by the International Association for the Study of Pain, Neuropathic Special Interest group as pain arising as a direct consequence of a lesion or disease affecting the somatosensory system. It can be caused by lesions of the peripheral or central nervous system or both. The nerves involved can then transmit abnormal or incorrect messages to the brain resulting in increased intensity of pain, pain over a larger area or persistent pain. Neuropathic pain episodes can be divided into spontaneous or stimulus-evoked pain i.e. sensory changes. It is estimated that neuropathic pain could be a significant feature in up to 40% of cancer pain syndromes and in one case series it was found that 79% of neuropathic pain cases result from nerve compression, 16% from nerve injury and 5% are sympathetically mediated 1. Nerve injury in cancer has 3 main causes: 1. Tumour infiltration of individual nerves, nerve plexuses or the spinal cord. 2. As a result of surgery (post-operative incisional pain and phantom limb pain). 3. Radiotherapy and chemotherapy can also damage nerves and alter nerve function. Other classical forms of neuropathic pain include diabetic peripheral neuropathy, trigeminal neuralgia and postherpetic neuralgia. Clinical Features Neuropathic pain may include some of the following features: Pain in the distribution of a nerve or dermatome Burning or stinging Deep aching pain Spontaneous stabbing/lancinating pain Numbness Allodynia (pain in response to a normally non-painful stimulus eg. Unable to tolerate clothes on the area) Dysaesthesia (altered sensations such as pins and needles) Hyperaesthesia (unpleasant increased sensitivity) Hyperalgesia (increased pain response to a normally painful stimulus) Occasionally a sympathetic component manifesting as cutaneous vasodilatation and/or sweating. The diagnosis of neuropathic pain is based mainly on the patient s history and physical examination. The essential elements are to identify painful symptoms, altered sensation and a clinical history that all match a neuroanatomical or dermatomal pattern. Examination may also identify specific functional neurological deficits. The LANSS scale is a useful screening tool (appendix 1), although it is not a substitute for good clinical assessment. Palliative care patients usually have a combination of neuropathic and nociceptive pain and it can be useful to consider whether there is a neuropathic component to an individual s pain. Page 1 of 9
2 Management As well as the pain, other physical and emotional aspects should be addressed including improving poor sleep as well as treating depression and anxiety. Non-pharmacological approaches should also be considered (see below). A multi-disciplinary approach is often the most successful. General recommendations for the medical management of neuropathic pain in non-palliative care patients would suggest the use of a tricyclic antidepressant or an anticonvulsant as first line analgesics. In palliative care, because a patient s pain is rarely purely neuropathic in origin, it is usually recommended to follow the WHO analgesic ladder with early consideration of adjuvant medications in addition. If pain is due to an infiltrating cancer, a combination of opioid and NSAID should be tried first, before adding an anti-depressant or anti-convulsant 2. About half of nerve injury pains caused by cancer respond to the combined use of a NSAID and a strong opioid; the rest need adjuvant analgesics 3. Responsiveness of the pain to medications may be reduced if pain has been present for a prolonged period prior to instigation of treatment. In one systematic review, the benefits of adjuvant analgesics greatly outweigh their adverse effects in patients with neuropathic cancer pain. No one adjuvant analgesic was better than another and none caused more side effects than another WHO Analgesic Ladder Opioids and Adjuvants Morphine should be 1 st line opioid of choice. There is no evidence that oxycodone or other opioids are superior to morphine in the management of neuropathic pain. Opioids are comparable to tricyclic antidepressants in number needed to treat (NNT) in non-cancer neuropathic pain (approx 2.5) 5. Tramadol - Do not use with antidepressants due to risk of serotonin toxicity. Limited evidence suggests NNT of approx Non-steroidal anti-inflammatory drugs can be tried as adjuvant analgesics. 2. Corticosteroids Steroids are only recommended for use in neuropathic pain caused by an infiltrating cancer. They can be very useful in reducing neuropathic pain due to nerve compression by reducing oedema and inflammation 6. They should be considered at any stage if nerve compression is felt likely. Starting dose 8mg od (but adjusted depending on the clinical situation). Remember gastric protection if needed and be vigilant for oral thrush and steroid induced diabetes. 3. Antidepressants Tricyclic Antidepressants (TCAs) eg. Amitriptyline, Nortriptyline, Imipramine, Lofepramine. Although very well established in palliative medicine, TCAs are unlicensed for neuropathic pain. The NNT for the different types of neuropathic pain that respond to TCAs ranges from 2.0 to The different types of tricyclic antidepressant have differing effectiveness and side effect profiles 5. Amitriptyline may cause a more significant morning hangover effect than nortriptyline 7. Side effects include dry mouth, constipation, postural hypotension, urinary retention and cardiac arrhythmias. They should be avoided in patients with glaucoma and used with caution in patients with a cardiac or diabetic history. TCAs should be the first line agent for treatment of neuropathic pain in patients with renal impairment. They should not be withdrawn abruptly. Page 2 of 9
3 Amitriptyline should be started at 10mg nocté. If tolerated it can be increased to 25mg after 3-7 days, then increased by 25mg every 1-2 weeks (up to maximum dose of 150mg od). Nortriptyline could be tried if amitriptyline is helpful but poorly tolerated (if total dose amitriptyline 100mg or less the same dose can be given without tapering or a wash-out period). Lofepramine has a lower incidence of side effects and may therefore be safer in patients with history of cardiac arrhythmias. Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin & Noradrenaline Reuptake Inhibitors (SNRIs) eg. Venlafaxine, Duloxetine, Paroxetine, Citalopram, Trazodone. Venlafaxine is the first-line antidepressant of choice in neuropathic pain from causes other than diabetic neuropathy 6. Side effects include nausea, constipation, hypertension, increased bleeding risk (if combined with NSAID) and should be avoided in patients with cardiac arrhythmias, severe renal or liver disease. They may be less likely to predispose to cardiac problems than TCAs. Venlafaxine should be started at a dose of 37.5mg daily and titrated up at weekly intervals to 150mg maximum dose. There is a risk of withdrawal syndrome and as such the dose should be reduced over several weeks. Duloxetine is the drug of choice in and only licensed for diabetic neuropathic pain. It should be started at 30mg daily and increased to a maximum of 120mg daily. 4. Antiepileptics Gabapentin or Pregabalin These should be considered as an alternative 1 st line therapy to tricyclic antidepressants (in patients without renal impairment) as there is no good evidence to suggest either class of drug is more effective. Advantages include the fact that they are licensed for neuropathic pain and have fewer anti-cholinergic side effects than amitriptyline. Side effects include dizziness, drowsiness, peripheral oedema and a dry mouth. Gabapentin: Pregabalin: It can involve a large tablet load and require careful titrating. Start at 100mg the first night then 100mg tds and titrate up to recommended maximum dose of 1200mg/day, (in certain circumstances this can be increased to 3600mg /day). Titration should be slow in elderly, frail patients (refer to PCF 4). It must be used in caution in renal failure (see appendix 2). The duration of an adequate trial of Gabapentin is 3-8 weeks titration plus 2 weeks at maximum dose. The brand name Lyrica is licensed for neuropathic pain but not the generic drug; it has lower NNH (number needed to harm) than Gabapentin in some studies 5 but can still have significant side effects. Starting dose is 25 to 50mg bd for most patients, titrating to 300mg bd maximum. Also use with caution in renal failure as the drug is excreted unchanged by the kidneys, and cardiac failure. Recommendations are for doses to be given once daily when egfr <30 (see appendix 2). NICE guidelines 6 recommend offering either Amitriptyline, Duloxetine, Gabapentin or Pregabalin as first line initial treatment for NP, and titrating the dose until either a therapeutic effect is achieved or side effects limit further titration. If the initial drug is ineffective or side effects are not tolerated, the recommendation is to switch to one of the remaining 3 drugs and repeat the process to find a drug that is effective and tolerated. If it is necessary to combine adjuvant analgesics then avoid combining two adjuvants with the same action. Page 3 of 9
4 Other Antiepileptics Sodium Valproate disadvantage is monitoring levels/bloods. Lamotrigine maybe useful. Is not licensed. Levetiracetam Carbamazepine first-line choice in Trigeminal Neuralgia but may be a useful alternative in some patients 7. Starting dose 100mg BD and titrate weekly to a maximum of 1.2 to 1.6mg daily. Oxcarbazepine may be less likely to cause blood disorders. 5. Consider Other Medications Clonazepam: Lidocaine: This is a benzodiazepine with long half-life. It can be useful when spasms or anxiety are associated with the pain. Start at 0.5mg nocté and titrate up to 2mg. A local anaesthetic available in 5% patches. Patch must be placed over the painful area to be effective. Leave in place for 12 hours & then remove for 12 hours to prevent tolerance. A two week trial is enough to assess efficacy 7. Can use up to 3 patches at any one time. (NB There is limited evidence for the effectiveness of such patches so it may be worth considering this as a trial only). NMDA receptor channel blockers: Ketamine: Methadone: Capsaicin Cream: Can cause opioid sparing and render patients opioid toxic so usually introduced as inpatient. Can be used orally (start at 10mg qds up to 200mg qds) or as a continuous subcutaneous infusion (CSCI). (Starting dose mg/kg/hr up to 2.4g/24hrs). Side effects include vivid dreams and hallucinations which can be controlled by haloperidol This is an opioid agonist, NMDA receptor blocker and serotonin re-uptake inhibitor with a possible role in reducing wind-up. It has a very long half-life and accumulates in tissues due to high lipid solubility 8. Hospice admission is suggested to convert a patient to methadone but it can be used in low dose (e.g. 5mg bd) as an adjuvant analgesic % can be useful to localise NP in those patients who wish to avoid or can t tolerate oral treatment 6. Tramadol: Might be useful as a breakthrough remedy while other drugs are being titrated Non-Drug Measures TENS: Discuss with Physiotherapist 7. Consult with Chronic Pain Team for Anaesthetic Interventions The Chronic Pain Team are located at Maidstone Hospital and can be contacted on / (Mon- Fri). Patients can be referred for out-patient appointments (at Maidstone, Tunbridge Wells or Sevenoaks Hospitals) or to be seen on IPU for assessment for a procedure. Procedures include nerve blocks, epidural or intrathecal injections, indwelling epidural or intrathecal infusions and nerve stimulation. Page 4 of 9
5 References 1. Stute P, Soukup J, Menzel M, Sabatowski R, Grond S. Analysis and treatment of different types of neuropathic cancer pain. J Pain and Symptom Management 2003; 26(6): Palliative Care Formulary 4 rd edition. Twycross R, Wilcock A. 3. Symptom Management in Advanced Cancer. Twycross R, Wilcock A, Stark Toller C, Jongen JLM et al. The Evidence for Pharmacological Treatment of neuropathic pain: beneficial and adverse effects. 5. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence-based proposal. Pain 2005; 118: NICE Guidelines: CG96173 Neuropathic pain - pharmacological management, Pub Nov West Kent CCG Neuropathic Pain Prescribing Guidelines, June Moulin DE et al. Pharmacological management of chronic neuropathic pain consensus statement and guidelines from the Canadian Pain Society. Pain Research and Management 2007; 12(1): Related policies and guidelines Epidural guideline (Inpatient Unit and Community) Date Originated: October 2007 Original Author: Date of last review: October 2012 Date of this review: April 2015 Reviewed By: Dr Diane Kooiman, Specialty Doctor Date of next review: January 2019 Issuing Authority: Dr Helen McGee, Consultant & Medical Director Page 5 of 9
6 The LANSS Pain Scale Leeds Assessment of Neuropathic Symptoms & Signs Appendix 1 Name Date. This pain scale can help to determine whether the nerves that are carrying your pain signals are working normally or not. It is important to find this out in case different treatments are needed to control your pain. A. PAIN QUESTIONNAIRE Think about how your pain has felt over the last week. Please say whether any of the descriptions match your pain exactly. 1) Does your pain feel like strange, unpleasant sensations in your skin? Words like pricking, tingling, pins and needles might describe these sensations. a) NO My pain doesn t really feel like this (0) b) YES I get these sensations quite a lot (5) 2) Does your pain make the skin in the painful area look different from normal? Words like mottled or looking more red or pink might describe the appearance. a) NO My pain doesn t affect the colour of my skin (0) b) YES I ve noticed that the pain does make my skin look different from normal (5) 3) Does your pain make the affected skin abnormally sensitive to touch? Getting unpleasant sensations when lightly stroking the skin, or getting pain when wearing tight clothes might describe the abnormal sensitivity. a) NO My pain doesn t make my skin abnormally sensitive in that area (0) b) YES My skin seems abnormally sensitive to touch I that area (3) 4) Does your pain come on suddenly and in bursts for no apparent reason when you re still. Words like electric shocks, jumping and bursting describe these sensations. a) NO My pain doesn t really feel like this (0) b) YES I get these sensations quite a lot (2) 5) Does your pain feel as if the skin temperature in the painful area has changed abnormally? Words like hot and burning describe these sensations. a) NO I don t really get these sensations (0) b) YES I get these sensations quite a lot (1) B. SENSORY TESTING Skin sensitivity can be examined by comparing the painful area with a contralateral or adjacent non-painful area for the presence of allodynia and an altered pin-prick threshold (PPT). 1) ALLODYNIA Examine the response to lightly stroking cotton wool across the non-painful area and then the painful area. If normal sensations are experienced in the non-painful site, but pain or unpleasant sensations (tingling, nausea) are experienced in the painful area when stroking, allodynia is present a) NO normal sensation in both areas (0) b) YES allodynia in painful area only (5) 2) ALTERED PIN-PRICK THRESHOLD Determine the pin-prick threshold by comparing the response to a 23 gauge (blue) needle mounted inside a 2ml syringe barrel placed gently onto the skin in a non-painful and then painful area. If a sharp pin prick is felt in the non-painful area, but a different sensation is experienced in the painful area, eg non/blunt only (raised PPT) or a very painful sensation (lowered PPT), an altered PPT is present. If a pin prick is not felt in either area, mount the syringe onto the needle to increase the weight and repeat. a) NO equal sensation in both areas (0) b) YES altered PPT in painful area (3) SCORING: Add values in parentheses for sensory description and examination findings to obtain overall score. TOTAL SCORE (maximum 24) If score <12, neuropathic mechanisms are unlikely to be contributing to the patient s pain. If score >12, neuropathic mechanisms are likely to be contributing to the patient s pain. Page 6 of 9
7 Page 7 of 9
8 Appendix 2 Page 8 of 9
9 Appendix 2 continued Page 9 of 9
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationNeuropathic Pain in Palliative Care
Neuropathic Pain in Palliative Care Neuropathic Pain in Advanced Cancer Affects 40% of patients Multiple concurrent pains are common Often complex pathophysiology with mixed components Nocioceptive Neuropathic
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationPain management in palliative care. Dr. Stepanie Lippett and Sister Karen Davies-Linihan
Pain management in palliative care Dr. Stepanie Lippett and Sister Karen Davies-Linihan contents Concept of total pain Steps in pain management Recognising neuropathic pain WHO analgesic ladder Common
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationNeuropathic Pain. Scott Magnuson, MD Pain Management of North Idaho, PLLC
Neuropathic Pain Scott Magnuson, MD Pain Management of North Idaho, PLLC Pain is our friend "An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described
More informationPregabalin Prescribing in Primary Care Audit Results 2012/13
Executive summary Pregabalin Prescribing in Primary Care Audit Results 2012/13 Pregabalin is extensively used across Aneurin Bevan Health Board (ABHB). It is the second highest medicine in terms of primary
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationNeuropathic Pain. Griffith Research Online. Author. Published. Journal Title. Copyright Statement. Downloaded from. Link to published version
Griffith Research Online https://research-repository.griffith.edu.au Neuropathic Pain Author Hall, Tony Published 2010 Journal Title Australian Journal of Pharmacy Copyright Statement Copyright 2010 Australian
More informationPain Management Documents
Pain Management Documents Prescriber and Patient Resources Non-cancer Pain Guidance Neuropathic Pain Guidance Stopping or Switching low strength Buprenorphine Patches Red and Yellow Flags Medicines Management
More informationPain. Christine Illingworth. Community Nurse St Luke s Hospice 17/5/17
Pain Christine Illingworth Community Nurse St Luke s Hospice 17/5/17 What is pain? Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage Pain is whatever
More informationPain. November 1, 2006 Dr. Jana Pilkey MD, FRCP(C) Internal Medicine, Palliative Medicine
Pain November 1, 2006 Dr. Jana Pilkey MD, FRCP(C) Internal Medicine, Palliative Medicine Objectives To be able to define pain To be able to evaluate pain To be able to classify types of pain To learn appropriate
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationNeuropathic pain MID ESSEX LOCALITY
Neuropathic pain Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system. A. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) i Read questions to
More informationVarious Types of Pain Defined
Various Types of Pain Defined Pain: The International Association for the Study of Pain describes pain as, An unpleasant sensory and emotional experience associated with actual or potential tissue damage,
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationNon-opioid and adjuvant pain management
Non-opioid and adjuvant pain management ALLISON JORDAN, MD, HMDC MEDICAL DIRECTOR OF PALLIATIVE CARE SERVICES CHRISTIAN AND ALTON MEMORIAL HOSPITALS ASSOCIATE MEDICAL DIRECTOR, BJC HOSPICE ASSISTANT PROFESSOR
More informationMedications for the Treatment of Neuropathic Pain
Medications for the Treatment of Neuropathic Pain February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation Neuropathic Pain Pain, paresthesias, and sensory
More informationEnhanced Community Palliative Support Services. Lynne Ghasemi St Luke s Hospice
Enhanced Community Palliative Support Services Lynne Ghasemi St Luke s Hospice Learning Outcomes Define the different types of pain Describe the process of pain assessment Discuss pharmacological management
More informationSpinal Cord Injury Pain. Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018
Spinal Cord Injury Pain Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018 Objectives At the conclusion of this session, participants should be able to: 1. Understand the difference between nociceptive
More informationPain CONCERN. Medicines for long-term pain. Antidepressants
Pain CONCERN Medicines for long-term pain Antidepressants Many people living with long-term pain (also known as chronic or persistent pain) are worried about using medicines like antidepressants. They
More informationAcute Pain NETP: SEPTEMBER 2013 COHORT
Acute Pain NETP: SEPTEMBER 2013 COHORT Pain & Suffering an unpleasant sensory & emotional experience associated with actual or potential tissue damage, or described in terms of such damage International
More informationNeuropathic pain (pain due to nerve damage)
Neuropathic pain (pain due to nerve damage) Clinical Guideline Pain can be nociceptive, neuropathic or mixed. The neuropathic component of pain generally responds poorly to conventional analgesics. Consider
More informationGateshead Pain Guidelines for Chronic Conditions
Gateshead Pain Guidelines for Chronic Conditions Effective Date: 13.2.2013 Review Date: 13.2.2015 Gateshead Pain Guidelines: Contents PAIN GUIDELINES Chronic Non-Malignant Pain 5 Musculoskeletal Pain 6
More informationAcute pain management in opioid tolerant patients. Muhammad Laklouk
Acute pain management in opioid tolerant patients Muhammad Laklouk General principles An adequate review and assessment Provision of effective analgesia (including attenuation of tolerance and hyperalgesia)
More informationPAIN TERMINOLOGY TABLE
PAIN TERMINOLOGY TABLE TERM DEFINITION HOW TO USE CLINICALLY Acute Pain Pain that is usually temporary and results from something specific, such as a surgery, an injury, or an infection Addiction A chronic
More informationMANAGEMENT OF DIABETIC NEUROPATHY. Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D.
MANAGEMENT OF DIABETIC NEUROPATHY Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D. The Diabetic neuropathy cannot be reversed Not to restore function to damaged nerve Slowly progress no initial
More informationManagement of Pain related to Spinal Cord Lesion
Management of Pain related to Spinal Cord Lesion A Neurologist s Perspective Vincent Mok, MD Associate Professor Division of Neurology Department of Medicine and Therapeutics The Chinese University of
More informationOverview of Neuropathic pain
Overview of Neuropathic pain Kongkiat Kulkantrakorn,M.D. Neurology division Thammasat University 1 Contents Overview of pain New concepts and mechanism Treatment options New data in management 2 3 Breaking
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationPharmacological treatment of Pain
Pharmacological treatment of Pain None Disclosures and Conflict of Interest Dr John F. Flannery Medical Director MSK and Multisystem Rehab Program PMR - FRCPC Objectives At the end of this presentation
More information21 st June BDS BASHD Therapeutics Pain and Analgesia. BASHD Therapeutics Analgesics and Pain Management. Links to other BASHD content
Volume of Prescribing by Dentists 2011 ( a reminder) BASHD Therapeutics Analgesics and Pain Management Analgesics account for 1 in 80 dental prescriptions made A lot more analgesics will be suggested for
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: HIM.PA.64 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationIn our patients the cause of seizures can be broadly divided into structural and systemic causes.
Guidelines for the management of Seizures Amalgamation and update of previous policies 7 (Seizure guidelines, ND, 2015) and 9 (Status epilepticus, KJ, 2011) Seizures can occur in up to 15% of the Palliative
More informationPOST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS
POST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS November 9, 2018 Aimee LaMere, CNP Molly McNaughton, CNP Leslie Weide, MSW, LICSW, ACM Disclosures: Conflict of interest statement: We certify that,
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationREFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - Executive Summary Table below provides a summary of the key metrics for Qutenza in the 7MM neuropathic pain markets during
More informationManagement of neuropathic pain (non-malignant) Medicines Initiation Protocol
Introduction Management of neuropathic pain (non-malignant) Medicines Initiation Protocol Pain is one of the most common reasons that patients present to Primary Care It is known that there are widespread
More informationComplicated pain. Dr Stephanie Lippett
Complicated pain Dr Stephanie Lippett UK incidence & prevalence of cancer pain 1% of UK population are living with cancer at present 70% of cancer patients experience pain 70-90% of patients with advanced
More informationDiabetic Peripheral Neuropathic Pain: Evaluating Treatment Options
Diabetic Peripheral Neuropathic Pain: Evaluating Treatment Options Ramon L. Cuevas-Trisan, MD Disclosures Speakers Bureau/Honoraria: Allergan, Ipsen 1 Learning Objectives Discuss practical approaches to
More informationGuidelines for the Pharmacological Management of Chronic Pain in Primary Care. December 2012
Guidelines for the Pharmacological Management of Chronic Pain in Primary Care December 2012 NHS Portsmouth CCG Fareham and Gosport CCG South Eastern Hampshire CCG 1 Guidelines for the Pharmacological Management
More informationVolume 4; Number 5 May 2010
Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationREFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - Executive Summary Table below provides a summary of the key metrics for Lidoderm/Versatis in the 7MM neuropathic
More informationSHARED CARE GUIDELINE For
SHARED CARE GUIDELINE For Ketamine in Palliative Care Implementation Date: 26.1.2011 Review Date: 26.1.2013 This guidance has been prepared and approved for use within Gateshead in consultation with Primary
More informationPain control in Cancer patients. Dr Ali Shoeibi, Assistant Professor of Neurology
Pain control in Cancer patients Dr Ali Shoeibi, Assistant Professor of Neurology More than two thirds of patients with advanced cancer experience cancer pain Almost all pain can be controlled to some extent
More informationSharon A Stephen, PhD, ARNP, ACHPN. September 23, 2014
Sharon A Stephen, PhD, ARNP, ACHPN September 23, 2014 Case-based presentation selected to discuss: Pain assessment Barriers to adequate pain relief Pharmacologic interventions Non-Pharmacologic interventions
More informationAdvice following an Independent Review Panel (IRP)
Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationNon Malignant Pain: Symptom Management
Non Malignant Pain: Symptom Management Renal Care Symposium July 2018 Anica Vasic Pain Management Unit St George Hospital Definitions Prevalence Assessment Treatment Medications Newer agents: tapentadol,
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationGUIDELINES ON PAIN MANAGEMENT IN UROLOGY
GUIDELINES ON PAIN MANAGEMENT IN UROLOGY F. Francesca (chairman), P. Bader, D. Echtle, F. Giunta, J. Williams Eur Urol 2003; 44(4):383-389 Introduction Pain is defined as an unpleasant sensory and emotional
More informationNon-Opioid Drugs to Treat Neuropathic Pain. March 2018
Non-Opioid Drugs to Treat Neuropathic Pain Final Report March 2018 This report is intended only for state employees in states participating in the Drug Effectiveness Review Project (DERP). Do not distribute
More informationGUIDELINE FOR MANAGING NEUROPATHIC PAIN IN PRIMARY CARE
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) GUIDELINE FOR MANAGING NEUROPATHIC PAIN IN PRIMARY CARE This is an updated guideline that includes recommendations from NICE CG173 This guideline presents
More informationPain Signaling Neuropathic Pain Distinctly different from nociceptive pain Sustained by abnormal processing of sensory input by the peripheral or cent
Objectives Pharmacologic Management of Neuropathic Pain Joseph R. Ineck, Pharm.D.,., CPE Pharmacist: St. Luke s Health System At the conclusion of this presentation, pharmacists will be able to: 1. Differentiate
More informationThe pain of it all. Rod MacLeod MNZM. Hibiscus Hospice, Auckland and University of Auckland
The pain of it all Rod MacLeod MNZM Hibiscus Hospice, Auckland and University of Auckland Definition of PAIN An unpleasant sensory and emotional experience which we primarily associate with tissue damage
More information3/1/2018. Disclosures. Objectives. Clinical advisory board member- Daiichi Sankyo
Adjuvant pain medications in geriatrics Thomas B. Gregory, Pharm.D., BCPS, CPE, FASPE Clinical Pharmacy Specialist Pain Management CoxHealth Springfield, MO Disclosures Clinical advisory board member-
More informationPain Management Strategies Webinar/Teleconference
Pain Management Strategies Webinar/Teleconference Barry K. Baines, MD April 16, 2009 Objectives Describe the principles of pain management. Identify considerations in the use of opioids. Describe the benefits
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Generalised anxiety disorder Generalised anxiety disorder (GAD) is an umbrella term that covers a wide range of anxiety disorders
More informationDiabetic Peripheral Neuropathy: Assessment and Treatment
Diabetic Peripheral Neuropathy: Assessment and Treatment Denise Soltow Hershey PhD, FNP-BC Michigan Council of Nurse Practitioners Annual Conference March 17, 2018 Objectives 1) Describe the clinical features
More informationTreating Pain and Depression
Treating Pain and Depression Without Getting Depressed Joseph P, Arpaia, MD www.jparpaiamd.com More than 50% of patients with chronic pain also have clinically significant depression. Interestingly that
More informationCONCORD INTERNAL MEDICINE. Peripheral Neuropathy. April 22, 2012
CONCORD INTERNAL MEDICINE Peripheral Neuropathy Douglas G. Kelling, Jr., MD C. Gismondi-Eagan, MD, FACP George C. Monroe, III, MD April 22, 2012 The information contained in this protocol should never
More informationKetamine for Pain Control in Palliative care: A Guide for Patients
Ketamine for Pain Control in Palliative care: A Guide for Patients Introduction This leaflet provides information on a medicine called ketamine, which can be used to treat pain that is difficult to control.
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationCorporate Medical Policy
Corporate Medical Policy Intravenous Anesthetics for the Treatment of Chronic Pain File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intravenous_anesthetics_for_the_treatment_of_chronic_pain
More informationAnalgesia in patients with impaired renal function Formulary Guidance
Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function
More informationManaging the Chronic Pain Patient. (and some stuff about opioids)
Managing the Chronic Pain Patient. (and some stuff about opioids) C. Patrick Carroll, M.D. Assistant Professor Johns Hopkins University School of Medicine Department of Psychiatry and Behavioral Sciences
More informationREFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Neuropathic Pain (NP) in the US The US NP market was valued
More informationRegional Renal Training
Regional Renal Training Palliative and End of Life Care Dr Clare Kendall North Bristol NHS Trust Advanced Kidney Disease Dialysis/Transplant Conservative Management Deteriorating despite dialysis/failing
More informationTUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees Neuropathic Pain
1. Medical Condition Neuropathic pain is defined as pain that results from a lesion or disease in the somatosensory system. Neuropathic pain is frequently difficult to treat, and commonly interferes with
More informationA Pain Management Primer for Pharmacists. Jessica Geiger-Hayes, PharmD, BCPS, CPE Andrea Wetshtein, PharmD, BCPS, CPE
A Pain Management Primer for Pharmacists Jessica Geiger-Hayes, PharmD, BCPS, CPE Andrea Wetshtein, PharmD, BCPS, CPE Objectives Discuss the differences between somatic, visceral, and neuropathic pain Design
More informationGabapentin and pregabalin
Pain CONCERN Medicines for long-term pain Gabapentin and pregabalin This leaflet is about gabapentin and pregabalin, two drugs which are part of a group sometimes called gabapentinoids. The leaflet will
More information5.9. Rehabilitation to Improve Central Pain
5.9. Rehabilitation to Improve Central Pain Evidence Tables and References Canadian Best Practice Recommendations for Stroke Care 2011-2013 Update Last Updated: June 25 th, 2013 Contents Search Strategy...
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress REDUCING THE PAIN FACTOR AN UPDATE ON PERI-OPERATIVE ANALGESIA Sandra Forysth, BVSc DipACVA Institute of Veterinary,
More informationI s s u e 1,
I s s u e 1, 2 0 1 4 Guidelines for the Pharmacological Treatment of Peripheral Neuropathic Pain: Expert Panel Recommendations for the Middle East Region EFNS guidelines on the pharmacological treatment
More informationPAIN MANAGEMENT IN UROLOGY
24 PAIN MANAGEMENT IN UROLOGY F. Francesca (chairman), P. Bader, D. Echtle, F. Giunta, J. Williams Eur Urol 2003; 44(4):383-389 Introduction Pain is defined as an unpleasant sensory and emotional experience
More informationHow do we treat migraine? New SIGN Guidelines
How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood
More informationVolume 9; Number 3 March 2015 PRESCRIBING AND DISPENSING PREGABALIN FOR NEUROPATHIC PAIN
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
More informationPainful Diabetic Neuropathy Effective Management. Ketan Dhatariya Consultant in Diabetes NNUH
Painful Diabetic Neuropathy Effective Management Ketan Dhatariya Consultant in Diabetes NNUH Neuropathic Pain Prevalence varies between 10 and 90% depending on classification Accounts for 50-75% of non-traumatic
More informationCancer patients at End-of-Life: Multidimensional Pain Requiring Multimodal Therapy
Cancer patients at End-of-Life: Multidimensional Pain Requiring Multimodal Therapy Presented by: Marsha Farrell BSN, RN-BC, CHPN Pathways to Success Conference by the Bay November 12, 2014 Conflict of
More information9/30/2017. Case Study: Complete Pain Assessment and Multimodal Approach to Pain Management. Program Objectives. Impact of Poorly Managed Pain
Case Study: Complete Pain Assessment and Multimodal Approach to Pain Management MARY BETH PARTYKA MSN ADULT NURSE PRACTITIONER ADVOCATE CHRIST MEDICAL CENTER ADULT PAIN SERVICE Program Objectives Identify
More informationPain in Residential Aged Care Facilities. Management Strategies
Pain in Residential Aged Care Facilities Management Strategies August 2005 T HE A USTRALIAN PAIN S OCIETY Summary S UMMARY Pain in Residential Aged Care Facilities - Management Strategies outlines good
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationInterprofessional Webinar Series
Interprofessional Webinar Series Drug Therapy for Neuropathic Pain in the Medically Ill Russell K. Portenoy, MD Executive Director, MJHS Institute for Innovation in Palliative Care Chief Medical Officer,
More informationPersistent Pain in Secure Environments Health and Justice Pharmacy Network Meeting Tuesday 18 March 2014
Persistent Pain in Secure Environments Health and Justice Pharmacy Network Meeting Tuesday 18 March 2014 Dr Iain Brew Vice Chair RCGP SEG Health & Justice CRG Member Special Considerations General reluctance
More informationDoncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary
Doncaster & Bassetlaw Cancer Locality Palliative Core Formulary Approved by Doncaster & Bassetlaw Hospitals NHS Foundation Trust Drugs and Therapeutics Committee. DJ14/2155 Oct 2014 Review date: Oct 2017
More informationScottish Medicines Consortium
Scottish Medicines Consortium duloxetine 30mg and 60mg capsules (Cymbalta ) No. (285/06) Eli Lilly and Company Limited/Boehringer Ingelheim 4 August 2006 The Scottish Medicines Consortium has completed
More informationLearning Objectives. Perioperative goals. Acute Pain in the Chronic Pain Patient for Ambulatory Surgery 9/8/16
Acute Pain in the Chronic Pain Patient for Ambulatory Surgery Danielle Ludwin, MD Associate Professor of Anesthesiology Division of Regional and Orthopedic Anesthesia Columbia University Medical Center
More information10/08/59 PAIN IS THE MOST COMMON TREATABLE SYMPTOM OF CANCER CURRENT EVIDENCE BASED CONCEPTS: MANAGEMENT OF CANCER PAIN PAIN AN UNMET CLINICAL NEED IN
Pain is a frequent complication of cancer, and is common in many other life-limiting illnesses MANAGEMENT OF CANCER PAIN A/Prof Ghauri Aggarwal FRACP, FAChPM, FFPMANZCA Palliative Medicine Physician Sydney
More information01/07/2018 MANAGEMENT OF RECTAL TENESMUS PRESENTATION OUTLINE
MANAGEMENT OF RECTAL TENESMUS Dr. Áine Ní Laoire The Oxford Advanced Pain & Symptom Management Course Nottingham 27 th June 2018 PRESENTATION OUTLINE Definition A Clinical Case Epidemiology Pathophysiology
More informationPain is one of the most frequent clinical problems
Easing the Ouch: Relieving Short-Term Pain By Brian Goldman, MD, MCFP(EM) As presented at the Family Medicine Forum, Montreal, Quebec (November 8, 2002) Pain is one of the most frequent clinical problems
More information